HeartBeam Reports Second Quarter 2025 Results

What were HeartBeam's revenue and earnings per share for Q2 2025, and how do they compare to the same quarter last year? Did the company provide guidance for the remainder of 2025 or 2026, and what are the expectations for revenue and earnings? How did the reported revenue growth rate compare to consensus estimates and analyst expectations? Did HeartBeam disclose any updates on its pipeline, FDA approvals, or clinical trial progress? How does HeartBeam's valuation (P/E, EV/EBITDA, price-to-sales) compare to peers in the medical device/health‑tech sector? How did operating margins and cash flow performance change versus the prior quarter and year? What is the company's cash position and debt level, and are there any upcoming financing needs? Are there any notable changes in the management team or board that could impact execution? What are the analyst consensus rating and target price changes following the release? What were the primary drivers behind any changes in revenue, such as new product launches, regulatory approvals, or market expansion?